Anavex Life Sciences Corp.

Good morning and welcome to the Annevex Life Sciences fiscal 2025 third quarter conference call. My name is Clint Tomlinson and I will be your host for today's call. At this time all participants are in listen only mode and later we will conduct a question and answer session before or during this session we would like to ask a question. Please use the Q&A box or raise your hand. Please note this conference is being recorded and the call will be available on Annevex's website at .annevex.com later today. With us today is Dr. Christopher Misling, President and Chief Executive Officer and Sondar Bohnush, Principal Financial Officer. Before we begin please note that this conference call the company will make some projections and forward looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC and this includes without limitation the company's forms 10K and 10Q which identify specific factors that may cause actual results or events to differ material from those described in these forward looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital and maintenance of intellectual property rights. With that I'd like to turn the call over to Dr. Misling. Thank you, Clint and good morning

everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. Our development of non-invasive targeted upstream compounds continues to advance particularly in the context of Alzheimer's disease and schizophrenia. Clinical feedback highlights the importance of orally administered therapies that are both accessible and effective. At the recent Alzheimer's Association International Conference AAIC 2025 we presented open label extension data for Blakamizin which demonstrated continued clinically meaningful benefit in early stage Alzheimer patients. Further validating its therapeutic potential. In June 2025 a survey of Alzheimer's disease stakeholders from European Union member states on current unmet needs in Alzheimer care was conducted. There is a clear acknowledgement that oral therapies would facilitate things for many countries and be much more accessible for the respective healthcare systems. Potentially requiring less extensive monitoring and complex administration compared to injectable monoclonal antibodies. This modality difference is seen as a key factor in potential broader market penetration. At the end of July, Anevex was honored to be a part of the program at the 2025 Alzheimer's Association International Conference AAIC in Toronto. The sharing of knowledge at these central events is important to help advance dementia science to better support the millions of individuals, families and communities impacted by Alzheimer's disease. At the AAIC 2025 conference we were pleased to present the latest findings for Blakamizin. The data were presented by Marvin Zabak, professor of neurology and chairman of the advisory board of Anevex. The data showed that Blakamizin treated patients continued to accrue benefit through up to as measured by the pre-specified clinical endpoints, ADAS-Coq13 and ADCS-ADL respectively. Further presentations at the AAIC 2025 conference featured pre-specified precision medicine phase 2b-3 48-week Anevex -80-004 double-blind clinical trial data on Blakamizin, confirming the upstream mechanism of Blakamizin restoring impaired autophagy as an early event preceding amyloid beta and tau. And now I would like to direct the call to Sandra Boenisch, principal financial officer of Anevex for a financial summary of the recently reported quarter.

Thank you so much, Christopher, and good morning to everyone on the call. I am pleased to share with you today our third quarter financial results for our 2025 fiscal year. Our cash position on June 30th was $101.2 million and we had no debt. During the quarter, we utilized cash and cash equivalents of $12.5 million in operating activities after taking into account changes in non-cash working capital accounts. And as of the quarter end, we anticipate that the current adjusted cash utilization rate and range, an approximate runway of more than three years. Our research and development expenses for the quarter were $10 million as compared to $11.8 million for the comparable quarter of last year. General and administrative expenses were $4.5 million as compared to $2.8 million for the comparable quarter of last year. Compared to the same quarter of fiscal 2024, an increase in non-cash compensation charges was offset by a decrease in overall cash operating expenses due to the completion of a large manufacturing campaign at our Camazine to support execution and potential commercial readiness as we advance our therapeutic pipeline. And lastly, we reported a net loss of $13.2 million for the quarter or $0.16 per share. Thank you and back to you, Christopher.